Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept Pharmaceuticals Announces Publication Of Study Demonstrating Its Lead Compound Can Reverse Liver Fibrosis View HTML
Toggle Summary Liver And Metabolic Disease Company Intercept Pharmaceuticals To Present At Rodman & Renshaw Healthcare Conference
Company Also to Present Two Studies at The Liver Meeting™ Supporting Rationale
View HTML
Toggle Summary Intercept Pharmaceuticals Announces Closing Of New Financing Round
Company to Present at Rodman & Renshaw Global Healthcare Conference
View HTML
Toggle Summary Intercept Pharmaceuticals Closes $41 Million Equity Financing
Company Announces Lead Compound INT-747 Appears Well Tolerated in Phase 1 Study
View HTML
Toggle Summary Intercept Pharmaceuticals Expands Senior Management
Company establishes New COO Position, Announces Chief Medical Officer and Vice President, Program Management
View HTML
Toggle Summary Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer View HTML
Toggle Summary Intercept Pharmaceuticals Raises $25 Million
Funding Will Support Completion of INT-747 Phase II Clinical Trials and Acceleration of Pipeline Development
View HTML
Toggle Summary Nature Publication Reports on Key Roleof Bile Acids in Glucose Metabolism and Insulin Signaling View HTML
Toggle Summary Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity View HTML
Toggle Summary Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
Company to Present Data at EASD Plenary Session
View HTML